Myelo001 is a orally bioavailable small molecule developed by Myelo Therapeutics GmbH, Berlin, Germany. BioSputnik LLC works with Myelo Therapeutics GmbH to develop this molecule for the indication of chemotherapy-induced myelosuppression (CIM), radiation-induced myelosuppression (RIM), as well as acute radiation syndrome (ARS).